Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
SPX-101
DRUG
3 trials
Sponsors
Spyryx Biosciences, Inc.
, SparX Biotech(Jiangsu) Co., Ltd.
Conditions
Cystic Fibrosis
Solid Tumors
Phase 1
A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Completed
NCT03056989
Spyryx Biosciences, Inc.
Cystic Fibrosis
Start: 2017-05-31
End: 2017-08-02
Updated: 2017-09-05
Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors
Withdrawn
NCT05231733
SparX Biotech(Jiangsu) Co., Ltd.
Solid Tumors
Start: 2022-05-01
End: 2024-08-01
Updated: 2024-10-31
Phase 2
An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Completed
NCT03229252
Spyryx Biosciences, Inc.
Cystic Fibrosis
Start: 2017-08-01
End: 2019-06-20
Updated: 2019-12-30
Related Papers
First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers
ERJ Open Research
2020-12-10
9 citations
First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis.
2019-07-11
15 citations